Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives Average Recommendation of “Hold” from Analysts

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) have been assigned an average rating of “Hold” from the five brokerages that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating and three have issued a buy rating on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $5.50.

A number of equities research analysts have recently weighed in on MRVI shares. UBS Group reiterated a “reduce” rating on shares of Maravai LifeSciences in a research report on Wednesday. Weiss Ratings raised Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. Wall Street Zen upgraded Maravai LifeSciences from a “hold” rating to a “buy” rating in a research report on Saturday, May 23rd. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $6.00 price target on shares of Maravai LifeSciences in a research report on Friday, May 8th. Finally, Wells Fargo & Company boosted their price target on Maravai LifeSciences from $4.50 to $5.50 and gave the company an “overweight” rating in a research note on Friday, May 8th.

Maravai LifeSciences Stock Performance

MRVI stock traded down $0.01 during trading hours on Wednesday, hitting $4.82. 443,296 shares of the stock were exchanged, compared to its average volume of 1,793,087. Maravai LifeSciences has a 12 month low of $1.99 and a 12 month high of $4.99. The company has a current ratio of 5.91, a quick ratio of 4.96 and a debt-to-equity ratio of 0.72. The firm has a market capitalization of $1.24 billion, a P/E ratio of -6.79 and a beta of 0.72. The company has a 50-day simple moving average of $3.69 and a two-hundred day simple moving average of $3.55.

Maravai LifeSciences (NASDAQ:MRVI) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.05) by $0.06. Maravai LifeSciences had a negative net margin of 51.07% and a negative return on equity of 17.87%. The business had revenue of $65.84 million for the quarter, compared to the consensus estimate of $53.00 million. On average, analysts forecast that Maravai LifeSciences will post -0.2 earnings per share for the current fiscal year.

Institutional Trading of Maravai LifeSciences

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Royal Bank of Canada boosted its position in shares of Maravai LifeSciences by 49.0% during the 1st quarter. Royal Bank of Canada now owns 9,761 shares of the company’s stock worth $27,000 after acquiring an additional 3,209 shares in the last quarter. Sprott Inc. acquired a new stake in shares of Maravai LifeSciences in the 3rd quarter valued at $29,000. Quantessence Capital LLC bought a new position in shares of Maravai LifeSciences in the 3rd quarter valued at $31,000. Abel Hall LLC acquired a new position in shares of Maravai LifeSciences during the 3rd quarter worth $33,000. Finally, CIBC Bancorp USA Inc. bought a new stake in shares of Maravai LifeSciences during the 3rd quarter worth $33,000. Institutional investors own 50.25% of the company’s stock.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.